Travere Therapeutics Inc.
TVTX
|
$5.46
-4.88%
-5.13%
2M
|
Health Technology
(0.0% 1d) (-28.0% 1m) (-73.6% 1y) (0.0% 2d) (-7.8% 3d) (-4.7% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 415,554,206
http://www.travere.com
Sec Filling | Patents | 221 employees
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
add to watch list Paper trade email alert is off
Press-releases
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 07:00) - prnewswire.com
AKBA | $1.36 -0.73% -0.74% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.19%
C: 0.0%
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Published: 2024-04-04 (Crawled : 21:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -1.58%
H: 4.09%
C: 2.92%
metabolic genetic international disorders for therapeutics
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Published: 2024-04-03 (Crawled : 21:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 1.58%
H: 1.13%
C: -1.97%
filspari nephropathy congress association world therapeutics
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Published: 2024-03-28 (Crawled : 07:00) - prnewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 0.91%
H: 3.1%
C: -0.39%
AKBA | $1.36 -0.73% -0.74% 1.5M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approved treatment
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Published: 2024-03-19 (Crawled : 11:00) - prnewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -0.7%
H: 5.47%
C: 4.91%
ferinject health anemia approved treatment canada heart
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-13 (Crawled : 21:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -0.74%
H: 0.25%
C: -6.92%
nasdaq grants therapeutics
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -0.81%
H: 1.51%
C: -6.98%
filspari nephropathy drug approval food treatment application therapeutics
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 2.37%
H: 1.46%
C: 1.22%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.6%
HTGC 4 | $18.96 0.58% 0.0% 620K
|
Finance
|
| O: -2.77%
H: 0.47%
C: -0.27%
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 81.31%
H: 29.0%
C: 21.9%
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 2.1%
H: 2.83%
C: -0.5%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 14.46%
H: 11.02%
C: 4.72%
ALDX | $3.93 0.51% 0.51% 570K
|
Health Technology
|
| O: 1.91%
H: 2.68%
C: 1.07%
year financial results
Travere Therapeutics to Present at Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 22:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 2.37%
H: 1.46%
C: 1.22%
therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10